CLAIMS

1. A method of treating migraine in a patient in need thereof, comprising orally administering to the patient a fast-dispersing pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof.

2. The method according to Claim 1, wherein administering the pharmaceutical composition results in migraine pain freedom within 2 hours of the time of administration.

3. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 21.2% of patients achieving migraine pain freedom within 2 hours of the time of administration.

4. The method according to Claim 1, wherein administering the pharmaceutical composition results in freedom from most bothersome symptoms within 2 hours of the time of administration.

5. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 35.1% of patients achieving freedom from most bothersome symptoms within 2 hours of the time of administration.

6. The method according to Claim 5, wherein the most bothersome symptoms comprise photophobia, nausea, phonophobia, or a combination thereof.

7. The method according to Claim 1, wherein administering the pharmaceutical composition results in pain relief within 90 minutes of the time of administration.

8. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 49.6% of patients achieving pain relief within 90 minutes of the time of administration.

9. The method according to Claim 1, wherein administering the pharmaceutical composition results in achieving pain relief within 2 hours of the time of administration.

10. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 59.3% of patients achieving pain relief within 2 hours of the time of administration.

11. The method according to Claim 1, wherein administering the pharmaceutical composition results in sustained pain relief within 2 to 48 hours of the time of administration.

12. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 42.2% of patients achieving sustained pain relief within 2 to 48 hours of the time of administration.

13. The method according to Claim 1, wherein administering the pharmaceutical composition results in sustained pain freedom within 2 to 48 hours of the time of administration.

14. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 13.5% of patients achieving sustained pain freedom within 2 to 48 hours of the time of administration.

15. The method according to Claim 1, wherein administering the pharmaceutical composition results in reduced usage of rescue medication within 24 hours of the time of administration.

16. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 14.2% of patients using rescue medication within 24 hours of the time of administration.

17. The method according to Claim 1, wherein administering the pharmaceutical composition results in normal function within 2 hours of the time of administration.

18. The method according to Claim 1, wherein administering the pharmaceutical composition results in about 38.1% of patients reporting normal function within 2 hours of the time of administration.

19. The method according to Claim 1, wherein the daily dose of rimegepant is about 75 mg.

20. The method according to Claim 1, wherein the pharmaceutical composition is administered to a patient up to 15 times in a 30-day period.

21. The method according to Claim 1, wherein the pharmaceutically acceptable salt or rimegepant is rimegepant hemisulfate.

22. The method according to Claim 1, wherein the daily dose of rimegepant hemisulfate is about 85.65 mg.

23. The method according to Claim 1, wherein the pharmaceutical composition further includes benzyl alcohol, eucalyptol, gelatin, limonene, mannitol, menthol, menthone, menthyl acetate, sucralose, vanillin, or a combination thereof.

24. The method according to Claim 1, wherein about 1.3% or less of patients who received the pharmaceutical composition experience nausea.

25. The method according to Claim 1, wherein about 0.15% or less of patients who received the pharmaceutical composition experience hypersensitivity.

26. The method according to Claim 25, wherein the hypersensitivity comprises dyspnea, rash, or a combination thereof.